MedTrace Logo

Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma

NCT01247337 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2020-10-05

No results posted yet for this study

Summary

A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases from cholangiocarcinoma.

Conditions

Interventions

DRUG

Oxaliplatin, capecitabine, gemcitabine, cetuximab

Intrahepatic oxaliplatin

DRUG

Oxaliplatin, capecitabine, gemcitabine cetuximab

Oxaliplatin given intravenous

Sponsors & Collaborators

  • Dorte Nielsen

    lead OTHER

Principal Investigators

  • Magnus Bergenfeldt, Consultan · Department og Gastroenterology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-02
Primary Completion
2016-02-18
Completion
2016-02-18

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01247337 on ClinicalTrials.gov